Every 424B that Nrx Pharmaceuticals Inc (NRXP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NRXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXP filings page.
NRx Pharmaceuticals is offering 5,714,286 shares of Common Stock at $3.50 per share. The underwriters have a 30-day option to purchase up to an additional 857,142 shares. Delivery is expected on or about June 4, 2026. The prospectus states gross proceeds of $20,000,001.00 and estimated net proceeds to the company of approximately $18,800,000.94, or about $21,619,998.12 if the option is fully exercised. The number of shares expected to be outstanding after the offering is 36,228,993 (or 37,086,135 if the option is exercised), based on May 15, 2026 outstanding data.
The offering is being made under a shelf registration on Form S-3 and is a firm commitment underwriting led by BTIG with Lucid Capital Markets as joint bookrunner; net proceeds are stated to be for working capital and general corporate purposes.
NRx Pharmaceuticals, Inc. is offering shares of its common stock pursuant to a preliminary prospectus supplement dated June 2, 2026 under its Form S-3 shelf registration. The offering is described as a firm‑commitment, underwritten public offering with an underwriter option exercisable for 30 days; delivery is expected on or about June, 2026, subject to completion.
The prospectus supplement relies on the Base Prospectus from the company’s Form S-3 (File No. 333-288205) and discloses use of proceeds for working capital and general corporate purposes. The supplement cites 36,228,992 shares outstanding as of May 15, 2026 as the baseline share count used to compute pro forma figures.
NRx Pharmaceuticals is launching an at-the-market stock program to sell up to $20,000,000 of common stock through H.C. Wainwright & Co. as sales agent. Shares may be sold on Nasdaq under the symbol NRXP or in negotiated transactions at prevailing market prices, with HCW earning up to 3.0% of gross proceeds.
The company plans to use any net proceeds for working capital and general corporate purposes to support growth. As of September 30, 2025, net tangible book value was about $(1.02) per share, and an illustrative sale of 11,111,111 shares at $1.80 would leave pro forma net tangible book value at $(0.21) per share, creating immediate dilution of $2.01 per new share. The filing highlights significant risks, including potential dilution, stock price volatility, and possible Nasdaq delisting if listing requirements are not met.